Search

Your search keyword '"Montalban, X"' showing total 43 results
Start Over Author "Montalban, X" Publisher ovid technologies (wolters kluwer health)
43 results on '"Montalban, X"'

1. Defining the clinical course of multiple sclerosis: The 2013 revisions

Author

Lublin, F. D., primary, Reingold, S. C., additional, Cohen, J. A., additional, Cutter, G. R., additional, Sorensen, P. S., additional, Thompson, A. J., additional, Wolinsky, J. S., additional, Balcer, L. J., additional, Banwell, B., additional, Barkhof, F., additional, Bebo, B., additional, Calabresi, P. A., additional, Clanet, M., additional, Comi, G., additional, Fox, R. J., additional, Freedman, M. S., additional, Goodman, A. D., additional, Inglese, M., additional, Kappos, L., additional, Kieseier, B. C., additional, Lincoln, J. A., additional, Lubetzki, C., additional, Miller, A. E., additional, Montalban, X., additional, O'Connor, P. W., additional, Petkau, J., additional, Pozzilli, C., additional, Rudick, R. A., additional, Sormani, M. P., additional, Stuve, O., additional, Waubant, E., additional, and Polman, C. H., additional

Published
2014
Full Text
View/download PDF

2. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Author

Fox, R. J., primary, Cree, B. A. C., additional, De Seze, J., additional, Gold, R., additional, Hartung, H.-P., additional, Jeffery, D., additional, Kappos, L., additional, Kaufman, M., additional, Montalban, X., additional, Weinstock-Guttman, B., additional, Anderson, B., additional, Natarajan, A., additional, Ticho, B., additional, and Duda, P., additional

Published
2014
Full Text
View/download PDF

3. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis

Author

Comabella, M., primary, Caminero, A. B., additional, Malhotra, S., additional, Agullo, L., additional, Fernandez, O., additional, Reverter, F., additional, Vandenbroeck, K., additional, Rodriguez-Antiguedad, A., additional, Matesanz, F., additional, Izquierdo, G., additional, Urcelay, E., additional, Lopez-Larios, A., additional, Sanchez, A., additional, Otero, S., additional, Tintore, M., additional, and Montalban, X., additional

Published
2013
Full Text
View/download PDF

4. Value of NMO-IgG determination at the time of presentation as CIS

Author

Costa, C., primary, Arrambide, G., additional, Tintore, M., additional, Castillo, J., additional, Sastre-Garriga, J., additional, Tur, C., additional, Rio, J., additional, Saiz, A., additional, Vidal-Jordana, A., additional, Auger, C., additional, Nos, C., additional, Rovira, A., additional, Comabella, M., additional, Horga, A., additional, and Montalban, X., additional

Published
2012
Full Text
View/download PDF

5. A Genetic Model To Predict Response to Glatiramer Acetate Developed from a Genome Wide Association Study (GWAS) (S20.003)

Author

Macciardi, F., primary, Cohen, J., additional, Comabella Lopez, M., additional, Comi, G., additional, Cutter, G., additional, Eyal, E., additional, Filippi, M., additional, Levy, J., additional, Lublin, F., additional, Montalban, X., additional, Oksenberg, J., additional, Tchelet, A., additional, Weiss, S., additional, and Wolinsky, J., additional

Published
2012
Full Text
View/download PDF

8. RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168)

Author

Cree, B., primary, De Seze, J., additional, Fox, R., additional, Gold, R., additional, Hartung, H., additional, Jeffery, D., additional, Kappos, L., additional, Kaufman, M., additional, Montalban, X., additional, Weinstock-Guttman, B., additional, Natarajan, A., additional, Subramanyam, M., additional, Plavina, T., additional, Woodworth, J., additional, and Duda, P., additional

Published
2012
Full Text
View/download PDF

9. Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)

Author

Vollmer, T., primary, Comi, G., additional, Sorensen, P. S., additional, Arnold, D., additional, Filippi, M., additional, Statinova, O., additional, Kobys, T., additional, Becker, E., additional, Jeffery, D., additional, Montalban, X., additional, Kappos, L., additional, Boyko, A., additional, Selmaj, K., additional, Zipp, F., additional, Havrdova, E., additional, and Cohen, J., additional

Published
2012
Full Text
View/download PDF

10. Effects of a 24-Week Natalizumab Treatment Interruption on Quality of Life, Fatigue, and Cognition: Results from the RESTORE Study (P06.171)

Author

Weinstock-Guttman, B., primary, Cree, B., additional, De Seze, J., additional, Fox, R., additional, Gold, R., additional, Hartung, H., additional, Jeffery, D., additional, Kappos, L., additional, Kaufman, M., additional, Montalban, X., additional, Natarajan, A., additional, Morse, R., additional, Ticho, B., additional, and Duda, P., additional

Published
2012
Full Text
View/download PDF

11. BAF312, a Selective Sphingosine-1-Phosphate Receptor Modulator Improves MRI and Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (RRMS) (S30.001)

Author

Stuve, O., primary, Selmaj, K., additional, Li, D., additional, Hartung, H.-P., additional, Hemmer, B., additional, Kappos, L., additional, Freedman, M., additional, Rieckmann, P., additional, Montalban, X., additional, Zhang Auberson, L., additional, Pohlmann, H., additional, Mercier, F., additional, Dahlke, F., additional, and Wallstrom, E., additional

Published
2012
Full Text
View/download PDF

12. Early Initiation of Interferon Beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Clinical Outcomes and Use of Disease-Modifying Therapy from the BENEFIT Extension Study (PD5.002)

Author

Edan, G., primary, Kappos, L., additional, Montalban, X., additional, Polman, C., additional, Freedman, M., additional, Hartung, H., additional, Miller, D., additional, Barkhof, F., additional, Lanius, V., additional, Stemper, B., additional, Pohl, C., additional, Sandbrink, R., additional, and Pleimes, D., additional

Published
2012
Full Text
View/download PDF

14. Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132)

Author

Comi, G., primary, Vollmer, T., additional, Sorensen, P. S., additional, Arnold, D., additional, Filippi, M., additional, Statinov, O., additional, Kobys, T., additional, Becker, E., additional, Jeffery, D., additional, Montalban, X., additional, Kappos, L., additional, Boyko, A., additional, Selmaj, K., additional, Zipp, F., additional, Havrdova, E., additional, and Cohen, J., additional

Published
2012
Full Text
View/download PDF

15. A Genetic Model To Predict Response to Glatiramer Acetate Developed from a Genome Wide Association Study (GWAS) (IN3-2.003)

Author

Macciardi, F., primary, Cohen, J., additional, Comabella Lopez, M., additional, Comi, G., additional, Cutter, G., additional, Eyal, E., additional, Filippi, M., additional, Levy, J., additional, Lublin, F., additional, Montalban, X., additional, Oksenberg, J., additional, Tchelet, A., additional, Weiss, S., additional, and Wolinsky, J., additional

Published
2012
Full Text
View/download PDF

16. A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

Author

Gold, R., primary, Giovannoni, G., additional, Selmaj, K., additional, Havrdova, E., additional, Montalban, X., additional, Radue, E.-W., additional, Stefoski, D., additional, Robinson, R., additional, Riester, K., additional, Elkins, J., additional, and O'Neill, G., additional

Published
2012
Full Text
View/download PDF

18. Brainstem lesions in clinically isolated syndromes

Author

Tintore, M., primary, Rovira, A., additional, Arrambide, G., additional, Mitjana, R., additional, Rio, J., additional, Auger, C., additional, Nos, C., additional, Edo, M. C., additional, Castillo, J., additional, Horga, A., additional, Perez-Miralles, F., additional, Huerga, E., additional, Comabella, M., additional, Sastre-Garriga, J., additional, and Montalban, X., additional

Published
2010
Full Text
View/download PDF

19. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

Author

De Stefano, N., primary, Giorgio, A., additional, Battaglini, M., additional, Rovaris, M., additional, Sormani, M. P., additional, Barkhof, F., additional, Korteweg, T., additional, Enzinger, C., additional, Fazekas, F., additional, Calabrese, M., additional, Dinacci, D., additional, Tedeschi, G., additional, Gass, A., additional, Montalban, X., additional, Rovira, A., additional, Thompson, A., additional, Comi, G., additional, Miller, D. H., additional, and Filippi, M., additional

Published
2010
Full Text
View/download PDF

20. MRI criteria for MS in patients with clinically isolated syndromes

Author

Montalban, X., primary, Tintoré, M., additional, Swanton, J., additional, Barkhof, F., additional, Fazekas, F., additional, Filippi, M., additional, Frederiksen, J., additional, Kappos, L., additional, Palace, J., additional, Polman, C., additional, Rovaris, M., additional, de Stefano, N., additional, Thompson, A., additional, Yousry, T., additional, Rovira, A., additional, and Miller, D. H., additional

Published
2010
Full Text
View/download PDF

24. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment

Author

Polman, C. H., primary, Reingold, S. C., additional, Barkhof, F., additional, Calabresi, P. A., additional, Clanet, M., additional, Cohen, J. A., additional, Cutter, G. R., additional, Freedman, M. S., additional, Kappos, L., additional, Lublin, F. D., additional, McFarland, H. F., additional, Metz, L. M., additional, Miller, A. E., additional, Montalban, X., additional, O'Connor, P. W., additional, Panitch, H., additional, Richert, J. R., additional, Petkau, J., additional, Schwid, S. R., additional, Sormani, M. P., additional, Thompson, A. J., additional, Weinshenker, B. G., additional, and Wolinsky, J. S., additional

Published
2008
Full Text
View/download PDF

27. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Author

Koch, M. W., primary, Mostert, J. P., additional, de Vries, J. J., additional, De Keyser, J., additional, Kappos, L ., additional, Polman, C .H., additional, Freedman, M .S., additional, Edan, G ., additional, Hartung, H .-P., additional, Miller, D .H., additional, Montalban, X ., additional, Barkhof, F ., additional, Bauer, L ., additional, Pohl, C ., additional, and Sandbrink, R ., additional

Published
2007
Full Text
View/download PDF

31. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

Author

Sastre-Garriga, J., primary, Ingle, G. T., additional, Rovaris, M., additional, Téllez, N., additional, Jasperse, B., additional, Altmann, D. R., additional, Benedetti, B., additional, Stevenson, V. L., additional, Cercignani, M., additional, Leary, S. M., additional, Barkhof, F., additional, Brochet, B., additional, Dousset, V., additional, Filippi, M., additional, Montalban, X., additional, Kalkers, N. F., additional, Polman, C. H., additional, Rovira, À, additional, Miller, D. H., additional, and Thompson, A. J., additional

Published
2005
Full Text
View/download PDF

32. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

Author

Roxburgh, R. H.S.R., primary, Seaman, S. R., additional, Masterman, T., additional, Hensiek, A. E., additional, Sawcer, S. J., additional, Vukusic, S., additional, Achiti, I., additional, Confavreux, C., additional, Coustans, M., additional, le Page, E., additional, Edan, G., additional, McDonnell, G. V., additional, Hawkins, S., additional, Trojano, M., additional, Liguori, M., additional, Cocco, E., additional, Marrosu, M. G., additional, Tesser, F., additional, Leone, M. A., additional, Weber, A., additional, Zipp, F., additional, Miterski, B., additional, Epplen, J. T., additional, Oturai, A., additional, Sorensen, P. S., additional, Celius, E. G., additional, Lara, N. T., additional, Montalban, X., additional, Villoslada, P., additional, Silva, A. M., additional, Marta, M., additional, Leite, I., additional, Dubois, B., additional, Rubio, J., additional, Butzkueven, H., additional, Kilpatrick, T., additional, Mycko, M. P., additional, Selmaj, K. W., additional, Rio, M. E., additional, Sa, M., additional, Salemi, G., additional, Savettieri, G., additional, Hillert, J., additional, and Compston, D. A.S., additional

Published
2005
Full Text
View/download PDF

33. Corticosteroids, ibuprofen, and acetaminophen for IFNβ-1a flu symptoms in MS

Author

Río, J., primary, Nos, C., additional, Bonaventura, I., additional, Arroyo, R., additional, Genis, D., additional, Sureda, B., additional, Ara, J. R., additional, Brieva, L., additional, Martín, J., additional, Saiz, A., additional, Sánchez López, F., additional, Prieto, J. M., additional, Roquer, J., additional, Dorado, J. F., additional, and Montalban, X., additional

Published
2004
Full Text
View/download PDF

38. Primary and transitional progressive MS

Author

Stevenson, V.L., primary, Miller, D.H., additional, Rovaris, M., additional, Barkhof, F., additional, Brochet, B., additional, Dousset, V., additional, Filippi, M., additional, Montalban, X., additional, Polman, C.H., additional, Rovira, A., additional, de Sa, J., additional, and Thompson, A.J., additional

Published
1999
Full Text
View/download PDF

40. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis

Author

Sara Llufriu, Albert Saiz, Luisa M. Villar, Eva Borràs, Antonio J. Sánchez López, Manuel Comabella, Sergio Martínez-Yélamos, Eduard Sabidó, J.A. García-Merino, Rucsanda Pinteac, Lucienne Costa-Frossard, Yolanda Blanco, Xavier Montalban, Jaume Sastre-Garriga, Angela Vidal-Jordana, Nicolás Fissolo, Institut Català de la Salut, [Comabella M, Sastre-Garriga J, Pinteac R, Fissolo N, Vidal-Jordana A, Montalban X] Unitat de Neuroimmunologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borras E] Proteomics Unit, Universitat Pompeu Fabra, Barcelona. [Villar LM] Departments of Neurology and Immunology, Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid. [Saiz A] Service of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi Sunyer, University of Barcelona. [Martínez-Yélamos S] Department of Neurology, Bellvitge University Hospital, Barcelona, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Enzymes and Coenzymes::Enzymes::Hydrolases::Glycoside Hydrolases::Chitinases [CHEMICALS AND DRUGS], enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva [ENFERMEDADES], Esclerosi múltiple, Article, Multiple sclerosis, Glicosidases, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive [DISEASES], Internal medicine, Cathepsin L1, medicine, Humans, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [DISEASES], enzimas y coenzimas::enzimas::hidrolasas::glicósido hidrolasas::quitinasas [COMPUESTOS QUÍMICOS Y DROGAS], Shotgun proteomics, CSF albumin, biology, business.industry, Chitinases, Biochemical markers, Patient Acuity, Area under the curve, Middle Aged, Multiple Sclerosis, Chronic Progressive, Prognosis, Esclerosi múltiple - Prognosi, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad [ENFERMEDADES], Clinical trial, Neurology, Estudi de casos, Chitinase, Cohort, Marcadors bioquímics, Disease Progression, biology.protein, Biomarker (medicine), Female, Neurology (clinical), Case studies, business, Biomarkers, Follow-Up Studies
Abstract

ObjectiveThis study aimed to identify long-term prognostic protein biomarkers associated with disease progression in patients with progressive multiple sclerosis (MS).MethodsCSF samples were collected from a discovery cohort of 28 patients with progressive MS who participated in a clinical trial with interferon beta. Patients were classified into high and low disability progression phenotypes according to numeric progression rates (NPR) and step-based progression rates (SPR) after a mean follow-up time of 12 years. Protein abundance was measured by shotgun proteomics. Selected proteins from the discovery cohort were quantified by parallel reaction monitoring in CSF samples from an independent validation cohort of 41 patients with progressive MS classified also into high and low disability progression phenotypes after a mean follow-up time of 7 years.ResultsOf 2,548 CSF proteins identified in the discovery cohort, 10 were selected for validation based on their association with long-term disability progression: SPATS2-like protein, chitinase 3–like 2 (CHI3L2), plasma serine protease inhibitor, metallothionein-3, phospholipase D4, beta-hexosaminidase, neurexophilin-1, adipocyte enhancer-binding protein 1, cathepsin L1, and lipopolysaccharide-binding protein. Only CHI3L2 was validated, and patients with high disability progression exhibited significantly higher CSF protein levels compared with patients with low disability progression (p = 0.03 for NPR and p = 0.02 for SPR). CHI3L2 levels showed good performance to discriminate between high and low disability progression in patients with progressive MS (area under the curve 0.73; sensitivity 90% and specificity 63%).ConclusionsAlthough further confirmatory studies are needed, we propose CSF CHI3L2 as a prognostic protein biomarker associated with long-term disability progression in patients with progressive MS.Classification of EvidenceThis study provides Class II evidence that high CSF CHI3L2 levels identified higher disability progression in patients with progressive MS.

Published
2021

41. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Author

Fissolo, Nicolás, Pignolet, Beatrice, Rio, Jordi, Vermersch, Patrick, Ruet, Aurélie, deSèze, Jerome, Labauge, Pierre, Vukusic, Sandra, Papeix, Caroline, Martinez-Almoyna, Laurent, Tourbah, Ayman, Clavelou, Pierre, Moreau, Thibault, Pelletier, Jean, Lebrun-Frenay, Christine, Bourre, Bertrand, Defer, Gilles, Montalban, Xavier, Brassat, David, Comabella, Manuel, Universitat Autònoma de Barcelona, Universitat Autònoma de Barcelona (UAB), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Vall d'Hebron University Hospital [Barcelona], Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Physiopathologie de la Plasticité Neuronale (Neurocentre Magendie - U1215 Inserm), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), Nouvel Hôpital Civil de Strasbourg, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Neurologie [Aix-en-Provence], Centre Hospitalier du Pays d'Aix, Centre Hospitalier Universitaire de Reims (CHU Reims), Laboratoire de Psychopathologie et Neuropsychologie (LPN), Université Paris 8 Vincennes-Saint-Denis (UP8), CHU Clermont-Ferrand, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Nice (CHU Nice), Unité de Recherche Clinique de la Côte d’Azur [Nice] (URRIS UR2CA), Université Côte d'Azur (UCA), CHU Rouen, Normandie Université (NU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre d'Esclerosi Múltiple de Catalunya (CemCat), Vall d’Hebron Research Institute (VHIR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Lille Neurosciences & Cognition - U 1172 (LilNCog), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), CHU Bordeaux [Bordeaux], Service de Neurologie [Strasbourg], CHU Strasbourg-Hopital Civil, Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Service de Neurologie [Lyon], CHU Lyon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de neurologie [Reims], Service de Neurologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Nice], Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU), Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), HAL-SU, Gestionnaire, Institut Català de la Salut, [Fissolo N, Comabella M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Pignolet B] CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse, CPTP INSERM UMR 1043 CNRS UMR 5282 et Université de Toulouse III, UPS, France. [Rio J, Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vermersch P] Univ. Lille, Inserm U1172, CHU Lille, FHU Imminent, France. [Ruet A] CHU de Bordeaux, INSERM-CHU CIC-P 0005, Service de Neurologie, Bordeaux F-33076, France. Université de Bordeaux, Bordeaux F-33076, France. [deSèze J] Department of Neurology, Hôpital Civil, Strasbourg, Vall d'Hebron Barcelona Hospital Campus, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, Oncology, Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS], viruses, Other subheadings::Other subheadings::/drug therapy [Other subheadings], MESH: Multiple Sclerosis, Relapsing-Remitting / blood, 0302 clinical medicine, Natalizumab, Neurofilament Proteins, 030212 general & internal medicine, Prospective cohort study, MESH: Middle Aged, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Progressive multifocal leukoencephalopathy, Leukoencephalopathy, Progressive Multifocal, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], MESH: Multiple Sclerosis / diagnosis, virus diseases, MESH: Follow-Up Studies, Middle Aged, Prognosis, Clinical Practice, MESH: Immunologic Factors / administration & dosage, Neurology, MESH: Young Adult, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Cohort, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Multiple Sclerosis / drug therapy, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Otros calificadores::Otros calificadores::Otros calificadores::/sangre [Otros calificadores], medicine.drug, Adult, medicine.medical_specialty, Neurofilament, MESH: Multiple Sclerosis, Relapsing-Remitting / diagnosis, [SDV.IMM] Life Sciences [q-bio]/Immunology, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Filaments citoplasmàtics, sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS], Sensitivity and Specificity, Article, MESH: Prognosis, Multiple sclerosis, Young Adult, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, Internal medicine, parasitic diseases, MESH: Leukoencephalopathy, Progressive Multifocal / blood, medicine, Humans, Immunologic Factors, Other subheadings::Other subheadings::/blood [Other subheadings], In patient, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Leukoencephalopathy, Progressive Multifocal / diagnosis, MESH: Humans, business.industry, MESH: Multiple Sclerosis / blood, MESH: Adult, medicine.disease, MESH: Sensitivity and Specificity, MESH: Male, Class I, Avaluació de resultats (Assistència sanitària), MESH: Multiple Sclerosis, Relapsing-Remitting / drug therapy, Neurology (clinical), business, Esclerosi múltiple - Tractament, MESH: Female, MESH: Natalizumab / administration & dosage, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery, Follow-Up Studies, MESH: Neurofilament Proteins / blood
Abstract

ObjectivesThe study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple sclerosis (MS) and to discriminate PML from MS relapses.MethodsNFL levels were measured with single molecule array (Simoa) in 4 cohorts: (1) a prospective cohort of patients with MS who developed PML under NTZ therapy (pre-PML) and non-PML NTZ-treated patients (NTZ-ctr); (2) a cohort of patients whose blood was collected during PML; (3) an independent cohort of non-PML NTZ-treated patients with serum NFL determinations at 2 years (replication cohort); and (4) a cohort of patients whose blood was collected during exacerbations.ResultsSerum NFL levels were significantly increased after 2 years of NTZ treatment in pre-PML patients compared with NTZ-ctr. The prognostic performance of serum NFL levels to predict PML development at 2 years was similar in the NTZ-ctr group and replication cohort. Serum NFL levels also distinguished PML from MS relapses and were 8-fold higher during PML compared with relapses.ConclusionsThese results support the use of serum NFL levels in clinical practice to identify patients with relapsing-remitting MS at higher PML risk and to differentiate PML from clinical relapses in NTZ-treated patients.Classification of EvidenceThis study provides Class I evidence that serum NFL levels can identify NTZ-treated patients with MS who will develop PML with a sensitivity of 67% and specificity of 80%.

Published
2021

42. CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

Author

Fissolo, Nicolás, Matute-Blanch, Clara, Osman, Mohamoud, Costa, Carme, Pinteac, Rucsanda, Miró, Berta, Sanchez, Alex, Brito, Verónica, Dujmovic, Irena, Voortman, Margarete, Khalil, Michael, Borràs, Eva, Sabidó, Eduard, Issazadeh-Navikas, Shohreh, Montalban, Xavier, Comabella, Manuel, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Fissolo N, Matute-Blanch C, Costa C, Pinteac R, Brito V, Comabella Lopez M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Osman M] Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark. [Miró B] Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Sanchez A] Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Genetics, Microbiology and Statistics Department, Universitat de Barcelona, Spain. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Center for Multiple Sclerosis, St. Michael’s Hospital, University of Toronto, ON, Canada, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Enzims proteolítics - Inhibidors, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva [ENFERMEDADES], Esclerosi múltiple, Gastroenterology, factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS], Cohort Studies, Mice, 0302 clinical medicine, Esclerosi múltiple - Diagnòstic, aminoácidos, péptidos y proteínas::péptidos::serpinas [COMPUESTOS QUÍMICOS Y DROGAS], biology, medicine.diagnostic_test, Biochemical markers, Experimental autoimmune encephalomyelitis, Animal models in research, Enzyme inhibitors, Middle Aged, Multiple Sclerosis, Chronic Progressive, Neural stem cell, Cerebrospinal fluid, Neurology, Marcadors bioquímics, Biomarker (medicine), Female, Adult, medicine.medical_specialty, Encephalomyelitis, Autoimmune, Experimental, Immunofluorescence, Biological Factors::Biomarkers [CHEMICALS AND DRUGS], Neuroprotection, Article, Multiple sclerosis, 03 medical and health sciences, Downregulation and upregulation, 030225 pediatrics, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive [DISEASES], Internal medicine, medicine, Animals, Humans, In patient, Serpins, Serine protease, business.industry, Líquid cefalorraquidi, Correction, medicine.disease, Amino Acids, Peptides, and Proteins::Peptides::Serpins [CHEMICALS AND DRUGS], Mice, Inbred C57BL, 030104 developmental biology, Endocrinology, Inhibidors enzimàtics, biology.protein, Neurology (clinical), Models animals en la investigació, business, Biomarkers, 030217 neurology & neurosurgery
Abstract

Multiple sclerosis; SERPINA3 Esclerosi múltiple; SERPINA3 Esclerosis múltiple; SERPINA3 Objective To identify biomarkers associated with progressive phases of MS and with neuroprotective potential. Methods Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs). Results Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01). Conclusion These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS. This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; grant number PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS.

Published
2021

43. Chitinases and chitinase-like proteins as biomarkers in neurologic disorders

Author

Pinteac, Rucsanda, Montalban, Xavier, Comabella, Manuel, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Pinteac R, Comabella M] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Montalban X] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Nervous System Diseases [DISEASES], Enzymes and Coenzymes::Enzymes::Hydrolases::Glycoside Hydrolases::Chitinases [CHEMICALS AND DRUGS], enfermedades del sistema nervioso [ENFERMEDADES], Otros calificadores::Otros calificadores::Otros calificadores::/enzimología [Otros calificadores], Bioinformatics, Disease activity, Humans, Medicine, Sistema nerviós - Malalties - Tractament, enzimas y coenzimas::enzimas::hidrolasas::glicósido hidrolasas::quitinasas [COMPUESTOS QUÍMICOS Y DROGAS], Enzims - Metabolisme, Otros calificadores::Otros calificadores::/metabolismo [Otros calificadores], Views & Reviews, biology, business.industry, Chitinases, Other subheadings::Other subheadings::/metabolism [Other subheadings], Hexosaminidases, Neurology, Chitinase, biology.protein, Neurology (clinical), Nervous System Diseases, business, Other subheadings::Other subheadings::Other subheadings::/enzymology [Other subheadings], Biomarkers
Abstract

Esclerosi múltiple; Malaltia d'Alzheimer; Esclerosi lateral amiotròfica Esclerosis múltiple; Enfermedad de alzheimer; Esclerosis lateral amiotrófica Multiple sclerosis; Alzheimer's disease; Amyotrophic lateral sclerosis Chitinases are hydrolytic enzymes widely distributed in nature. Despite their physiologic and pathophysiologic roles are not well understood, chitinases are emerging as biomarkers in a broad range of neurologic disorders, where in many cases, protein levels measured in the CSF have been shown to correlate with disease activity and progression. In this review, we will summarize the structural features of human chitinases and chitinase-like proteins and their potential physiologic and pathologic functions in the CNS. We will also review existing evidence for the role of chitinases and chitinase-like proteins as diagnostic and prognostic biomarkers in inflammatory, neurodegenerative diseases, and psychiatric disorders. Finally, we will comment on future perspectives of chitinase studies in neurologic conditions. No targeted funding reported.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results